Non-neutralizing anti-aPC antibodies
The present invention provides anti-aPC antibodies that suppress the inactivation of activated protein C (aPC), and uses thereof. The present inventors screened anti-aPC antibodies, and succeeded in isolating anti-aPC antibodies comprising the activity of suppressing aPC inactivation in blood. The antibodies of the present invention can be used to maintain aPC activity by suppressing aPC inactivation, and can thus be used to sustain aPC bioactivities, such as the activity of suppressing activation of the blood coagulation system, and anti-inflammatory activity. In addition, the present invention provides uses of the antibodies of the present invention in aPC therapy for diseases such as thrombosis and sepsis. The therapeutic effect of aPC can be prolonged in treatment that uses aPC administration by allowing an antibody of the present invention to bind with aPC. The antibodies of the present invention can be used in the treatment and prevention of diseases such as thrombosis and sepsis.
1. An antibody against protein C or activated protein C (aPC), comprising the heavy chain complementarity determining regions (CDRs) 1, 2, and 3 having the sequences of SEQ ID NOs: 9, 10, and 11, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 21, 22, and 23, respectively.
2. The antibody of claim 1 , wherein the antibody is selected from the group consisting of a chimeric antibody, antibody fragment, single-chain antibody, and diabody.
3. A composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
4. The antibody of claim 1 , wherein the antibody is a human antibody or a humanized antibody.
5. An antibody that binds to the same epitope of protein C or aPC as an antibody comprising the CDR sequences of any of one of:
(a) the heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 9, 10, and 11, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 21, 22, and 23, respectively;
(b) heavy chain CDRs 1,2, and 3 having the sequences of SEQ ID NOs: 31, 32, and 33, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 24, 25 and, 34, respectively; or
(c) heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 15, 16, and 17, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 27, 28, and 29, respectively.
6. The antibody of claim 5 , wherein the antibody is selected from the group consisting of a human antibody, humanized antibody, chimeric antibody, antibody fragment, single-chain antibody, and diabody.
7. A composition comprising the antibody of claim 5 and a pharmaceutically acceptable carrier.
8. An antibody against protein C or aPC comprising heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 31, 32, and 33, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 24, 25 and, 34, respectively.
9. The antibody of claim 8 , wherein the antibody is a human antibody or a humanized antibody.
10. The antibody of claim 8 , wherein the antibody is selected from the group consisting of a chimeric antibody, antibody fragment, single-chain antibody, and diabody.
11. A composition comprising the antibody of claim 8 and a pharmaceutically acceptable carrier.
12. An antibody against protein C or aPC comprising heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 15, 16, and 17, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 27, 28, and 29, respectively.
13. The antibody of claim 12 , wherein the antibody is a human antibody or a humanized antibody.
14. The antibody of claim 12 , wherein the antibody is selected from the group consisting of a chimeric antibody, antibody fragment, single-chain antibody, and diabody.
15. A composition comprising the antibody of claim 12 and a pharmaceutically acceptable carrier.